Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 15/20 | 0.43 |
| ▸ | ELOC | Q15369 | 4/20 | 0.41 |
| ▸ | ELOB | Q15370 | 4/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554512 | 1.00 | VHL (0.43) | VHLELOCELOBTGM2DPP4 | |
| SCHEMBL21554492 | 1.00 | VHL (0.43) | VHLELOCELOBTGM2DPP4 | |
| SCHEMBL21554494 | 1.00 | VHL (0.43) | VHLELOCELOBTGM2DPP4 | |
| SCHEMBL22138839 | 0.90 | VHL (0.41) | VHLELOCELOBTGM2DPP4 | |
| SCHEMBL23183583 | 0.85 | VHL (0.41) | VHLELOCELOBDPP4DPP8 | |
| SCHEMBL21554539 | 0.85 | VHL (0.41) | VHLELOCELOBDPP4DPP8 | |
| SCHEMBL20419046 | 0.85 | VHL (0.41) | VHLELOCELOBDPP4DPP8 | |
| SCHEMBL21554505 | 0.85 | VHL (0.41) | VHLELOCELOBDPP4DPP8 | |
| SCHEMBL24558588 | 0.83 | DPP4 (0.36) | VHLELOCELOBDPP4DPP8 | |
| SCHEMBL24239716 | 0.82 | DPP4 (0.35) | VHLELOCELOBDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | VHL 216/4885ELOC 390/4885ELOB 285/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | VHL 266/4885ELOC 2705/4885ELOB 2627/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | VHL 216/4885ELOC 390/4885ELOB 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.